Key result
Ranolazine suppressed the induction of acetylcholine-mediated atrial flutter and fibrillation in 76% of anesthetized rabbits by significantly increasing atrial postrepolarization refractoriness.
Why the study?
Does ranolazine suppress the induction of acetylcholine-mediated atrial flutter and fibrillation in an intact rabbit model?
Does ranolazine suppress the induction of acetylcholine-mediated atrial flutter and fibrillation in an intact rabbit model?
Absolute Event Rate: 76% vs 0%
Ranolazine exerts antiarrhythmic activity by increasing atrial postrepolarization refractoriness, thereby suppressing the inducibility of acetylcholine-mediated atrial flutter and fibrillation in a rabbit model.
Hypothesis-generating for ranolazine in AF; should not change practice without human trials.
Ranolazine (Ran) is a novel anti-ischemic agent with electrophysiologic properties mainly attributed to the inhibition of late Na(+) current and atrial-selective early Na(+) current. However, there are only limited data regarding its efficacy and mechanism of action against atrial flutter (Afl) and atrial fibrillation (AF) in intact animals. Therefore, we aimed to investigate the electrophysiologic mechanism of Ran in a rabbit model of inducible atrial tachyarrhythmias elicited by acetylcholine (ACh). Arrhythmias were produced in 19 rabbits by rapid atrial burst pacing during control, after intravenous ACh and after Ran + ACh administration. Recording of right atrial monophasic action potentials (MAPs) and programmed stimulation were utilized to determine the duration of atrial repolarization at various cycle lengths and voltage levels of action potential, including 75% of total MAP duration (MAPD75), effective refractory period (ERP), and postrepolarization refractoriness (PRR = ERP - MAPD75) prior to and after Ran. Control stimulation yielded no arrhythmias or maximal nonsustained runs of Afl/AF. Upon ACh, 17 of 19 rabbits exhibited sustained Afl and AF as well as mixed forms of Afl/AF, while 2 animals revealed none or short runs of nonsustained arrhythmias and were excluded from the study. High-frequency burst pacing during the first 30 minutes after Ran + ACh failed to induce any arrhythmia in 13 of 17 rabbits (76%), while 2 animals displayed sustained Afl/AF and 2 other animals nonsustained Afl/AF. At basic stimulation cycle length of 250 milliseconds, Ran prolonged baseline atrial ERP (80 ± 8 vs 120 ± 9 milliseconds, P < .001) much more than MAPD75 (65 ± 7 vs 85 ± 7 milliseconds, P < .001), leading to atrial PRR which was more pronounced after Ran compared with control measurements (35 ± 11 vs 15 ± 10 milliseconds, P < .001). This in vivo study demonstrates that Ran exerts antiarrhythmic activity by suppressing inducibility of ACh-mediated Afl/AF in intact rabbits. Its action may predominantly be related to a significant increase in atrial PRR, resulting in depressed electrical excitability and impediment of arrhythmia initiation.
No takes yet. Share an insight, caveat, or question.
Aidonidis et al. (2012) studied Inducible atrial tachyarrhythmias (n=17). Ranolazine vs. Control (acetylcholine alone) was evaluated on Failure to induce any arrhythmia. Ranolazine suppressed the induction of acetylcholine-mediated atrial flutter and fibrillation in 76% of anesthetized rabbits by significantly increasing atrial postrepolarization refractoriness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: